Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | F3 | P13726 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.46 |
| ▸ | XDH | P47989 | 2/20 | 0.46 |
| ▸ | P4HB | P07237 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619991 | 1.00 | MAPT (0.50) | MAPTLMNAF3ALDH1A1RAB9A | |
| SCHEMBL25196614 | 0.94 | MAOB (0.55) | MAPTLMNAF3ALDH1A1RAB9A | |
| SCHEMBL21527703 | 0.94 | F3 (0.61) | MAPTLMNAF3ALDH1A1RAB9A | |
| SCHEMBL21527702 | 0.94 | F3 (0.61) | MAPTLMNAF3ALDH1A1RAB9A | |
| SCHEMBL25196646 | 0.94 | F3 (0.61) | MAPTLMNAF3ALDH1A1RAB9A | |
| SCHEMBL25223456 | 0.94 | MAPT (0.60) | MAPTLMNAALDH1A1RAB9ANPC1 | |
| SCHEMBL25223464 | 0.94 | MAOB (0.55) | MAPTLMNAF3ALDH1A1RAB9A | |
| SCHEMBL25196749 | 0.94 | MAPT (0.60) | MAPTLMNAALDH1A1RAB9ANPC1 | |
| SCHEMBL25202408 | 0.94 | TNFRSF1A (0.55) | MAPTLMNAF3ALDH1A1RAB9A | |
| SCHEMBL25219890 | 0.94 | MAPT (0.58) | MAPTLMNAALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-7276523-B2 | Aminopyridine derivatives as estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276523-B2 | Aminopyridine derivatives as estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276523-B2 | Aminopyridine derivatives as estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| US-20040152688-A1 | Aminopyridine derivatives as estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| WO-2002079163-A1 | AMINOPYRIDINE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152688-A1 | Aminopyridine derivatives as estrogen receptor modulators | ESR2, GPER1, ESR1 | MAPT 2628/4885LMNA 3601/4885F3 3332/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | MAPT 3297/4885LMNA 1180/4885F3 5/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885LMNA 1817/4885F3 11/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885LMNA 1817/4885F3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.